Kornimate/medical-research-clean huggingface dataset:
sleeping healthy/living healthy development

Conditions: Sleep; Psychological Stress

Summary: this pilot study will: (1) develop sleeping healthy/living healthy, a school-based health center (sbhc) intervention that combines mbih and sleep hygiene strategies to improve sleep quality in urban adolescents with poor sleep quality; (2) evaluate the feasibility and acceptability of intervention procedures; and (3) assess the preliminary intervention effects on sleep quality in urban adolescents. this study includes a development phase and a pilot individually-randomized group treatment (irgt) phase. in year 1, the investigators will develop the novel integrated intervention using an iterative participatory design process. in year 2, the investigators will conduct an irgt trial with 60 adolescents with insufficient sleep recruited from two sbhcs in new york city. adolescents will be randomized 1:1 to receive the intervention or an attention control of equal intensity and duration. process evaluation interviews guided by a rigorous fidelity framework with adolescents and with sbhc providers and personnel will be conducted to obtain feedback regarding intervention procedures.

poor sleep quality, which contributes to impaired functioning, is elevated in urban, ethnic/racial minority adolescents due, in part, to poor sleep hygiene. despite successful sleep hygiene interventions in younger children, none focus on adolescents, a group with unique developmental needs. urban adolescents face unique contextual stressors, which may contribute to ineffective use of sleep hygiene behaviors. mind-body integrative (mbih) approaches (e.g. yoga, meditation) improve sleep quality in adults, but are rarely applied to adolescents. mbih has been shown to reduce stress among adolescents. taken together, this suggests that integrating mbih with sleep hygiene strategies has the potential for a synergistic effect on improving sleep quality, yet no interventions concurrently use mbih and sleep hygiene with adolescents.

Eligibility criteria:
inclusion criteria: * age 13.0 -17.9; * grade 9 - 11; * currently enrolled as a patient in one of the participating sbhcs; and * report sleep duration \< 8 hours (below the minimally recommended number of hours of sleep for this age group through the following questions: what time do you: a) usually fall asleep on weekdays and b) usually wake up on weekdays?). exclusion criteria: * report of prior diagnosis of a sleep disorder, such as sleep disordered breathing, restless leg syndrome, or periodic limb movement; * significant developmental delay and/or severe psychiatric or medical conditions that preclude completion of study procedures or confound analyses; or * not capable of communicating (reading, speaking, writing) in english.
acupuncture in low anterior resection syndrome treatment

Conditions: Low Anterior Resection Syndrome

Summary: acupuncture has it's role in treating patients with fecal incontinence and diarrhea-predominant irritable bowel syndrome. there is no trial or case-report assessing it's role in treatment of low anterior resection syndrome.

colorectal cancer is common in western countries. for thirty years rectal cancer treatment is standardized: patients are undergoing low anterior resection with mesorectal excision +/- (chemo)radiotherapy. unfortunately around 80% of patients undergoing low anterior resection will experience complex bowel dysfunction including fecal incontinence, soiling, urgency, incomplete evacuation, fragmented defecation and impaired rectal sensation known as low anterior resection syndrome (lars) causing a "toilet dependence" which severely affects quality of life. still there is no standardized treatment for lars.

Eligibility criteria:
inclusion criteria: * patients over 18 year * signed written consent * patients experiencing major low anterior resection syndrome * patients at least one year following the surgery exclusion criteria: * allergy to stainless steal * implanted pacemaker * current skin infection * needle phobia * metastatic disease to the central nervous system (brain, spinal cord) * at the same time, application of smecta, dicetel, cisapride or traditional chinese medicine;
carboplatin in patients with progressive gliomas

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of carboplatin in patients with progressive glioma.

objectives: i. assess the response to carboplatin (cbdca) in patients with progressive low-grade gliomas. ii. assess the activity of cbdca in stabilizing the growth of these tumors. outline: single-agent chemotherapy. carboplatin, cbdca, nsc-241240. projected accrual: a total of 25 evaluable patients will be entered if there is at least 1 response in the first 9 patients.

Eligibility criteria:
disease characteristics: histologically confirmed primary intracranial low-grade glioma (i.e., astrocytoma or oligodendroglioma) no more than 2 years since tissue diagnosis biopsy not required for intrinsic chiasmatic mass or tumor infiltration along the posterior optic tracts evidence of progressive disease by at least one of the following: papilledema or other clinical sign of increased intracranial pressure documented change in neuroimaging studies, e.g.: hydrocephalus 25% increase in product of maximum perpendicular diameters of tumor the following are required in patients with optic pathway gliomas: progressive loss of vision documented by an ophthalmologist, i.e.: doubling of octaves (e.g., 20/20 to 20/40 or 20/40 to 20/80) on 2 successive visits loss of visual acuity not explainable by other causes, e.g., media abnormalities or amblyopia greater than 3 mm increase in proptosis at least 2 mm increase in diameter of optic nerve on neuroimaging increase in distribution of tumor involving the optic tracts or optic radiations demonstrated by ct or mri using t1 (with or without contrast) or t2 imaging patient characteristics: age: any age performance status: karnofsky 70%-100% life expectancy: at least 12 weeks hematopoietic: anc at least 1,500 platelets at least 100,000 hemoglobin at least 8.0 g/dl hepatic: bilirubin less than 1.5 times normal alt less than 1.5 times normal renal: creatinine less than 1.5 mg/dl other: negative pregnancy test required of fertile women effective contraception required of fertile patients prior concurrent therapy: at least 12 weeks since radiotherapy (4 weeks since other therapy) and recovered prior chemotherapy allowed with subsequent disease progression

Keywords: childhood low-grade cerebral astrocytoma recurrent adult brain tumor adult brain stem glioma childhood oligodendroglioma untreated childhood brain stem glioma recurrent childhood brain stem glioma untreated childhood visual pathway glioma recurrent childhood visual pathway glioma untreated childhood cerebellar astrocytoma recurrent childhood cerebellar astrocytoma recurrent childhood cerebral astrocytoma adult anaplastic astrocytoma adult oligodendroglioma
study on the ability of virtual reality glasses in anxiety and pain reduction in 50 women undergoing amniocentesis or feticide

Conditions: Anxiety Acute; Amniocentesis; Foeticide

Summary: both amniocenteses and especially feticide are procedures that incorporate both anxiety and pain. as anxiety and pain can be reduced when using a distraction, the investigators speculate that the use of virtual reality glasses during these procedures will elevate both anxiety and pain. the investigators will examine this hypothesis by comparing two groups of participants who undergo amniocentesis or feticide, one group will undergo the procedure while using virtual reality glasses and the other without the use of the glasses.


Eligibility criteria:
inclusion criteria: pregnant women undergoing amniocentesis/foeticide who will sign an informed consent form - exclusion criteria: * women younger than 18 years * twin pregnancies * women with vertigo
cardiac arest and genetic

Conditions: Out-of-hospital Cardiac Arrest

Summary: sudden death is a major problem in industrially developed countries. despite a decline in ischemic heart disease mortality and the progress has been made in resuscitation, treatment of sudden death victims is frequently unsuccessful. the ideal solution would be to prevent the disease process that causes the initial episode of cardiac arrest. parental sudden death is an independent risk factor for sudden death. so, detect a gene predisposing to sudden death may help provide better identification of subjects at high risk of cardiac arrest. this research is a genetic study of sudden cardiac death, recruited 2000 subjects in out-of-hospital cardiac arrest.


Eligibility criteria:
inclusion criteria: * ohca * aged from 18 to 75 years exclusion criteria: * pregnant * people not free * inhospital subjects * death by other disease * violent death
effect of amino acids and sugar alcohols on satiation peptides and activation of specific brain regions

Conditions: Endocrine System Diseases

Summary: with this study the investigators investigate the effects of amino acids (tryptophan, leucin) and sugar alcohols (xylitol, erythritol) on satiety mechanisms and brain activation.


Eligibility criteria:
inclusion criteria: * healthy normal weight subjects with a body-mass index of 19.0-24.9 * healthy obese subjects with a body-mass index of \> 30 * normal eating habits (no diets; no dietary changes; no special dietary habits such as vegetarian/vegan) * age 18-40 years * stable body weight for at least three months exclusion criteria: * smoking * substance abuse * regular intake of medications (except for oral contraceptives) * medical or psychiatric illness * history of gastrointestinal disorders * food allergies * pregnancy, breast feeding * body piercings that cannot be removed * history of claustrophobia * left-hander
preoperative methylprednisolone to patients suspected of appendicitis undergoing laparoscopy

Conditions: Suspected Appendicitis

Summary: to test whether 125 mg preoperative methylprednisolone intravenously can reduce postoperative pain after laparoscopy for suspected appendicitis and to test whether preoperative methylprednisolone can reduce postoperative fatigue, increase quality of sleep, reduce nausea or vomiting, reduce duration of convalescence and increase overall quality of recovery after laparoscopy for suspected appendicitis.

patients enrolled are randomized to active substance or placebo approximately 30 minutes prior to skin incision. patients are followed for 30 days postoperative with registration of outcomes on a postoperative questionnaire. patients are contacted by telephone at every registration time. the primary outcome is also secured over the telephone in case patients do not return their questionnaire. with a power of 80% and a significance level of 5% we need 64 patients (32 in each arm) to show a 30% reduction in postoperative pain during the first 3 postoperative days with 5 measurements and we need 42 patients (21 in each arm) to show a 15% increase in the qor-15 during the first 3 postoperative days. with an anticipated loss to follow up of 20% we need 80 patients ( 40 in each arm).

Eligibility criteria:
inclusion criteria: * laparoscopy for suspected appendicitis * age 18 years or older * american society of anesthesiologist (asa) class i-iii. * gives written and oral consent exclusion criteria: * known inflammatory bowel disease. * known autoimmune disease. * chronic pain patient. * presumed poor compliance. * pregnant or breastfeeding. * in systematic treatment with glucocorticoids or other immunosuppressive treatment. * known renal disease, gfr\<30. * known liver cirrhosis. * known heart failure, ef\<40%. * known glaucoma. * known ocular herpes simplex. * known cushings disease.

Keywords: acute surgery laparoscopy
short and mid-term repeatability of active anterior rhinomanometry (aar) measurements in paediatric age

Conditions: Rhinitis; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial

Summary: longitudinal, observational study to assess the short-term (test re-test) and mid-term (within the span of 28 days) repeatability of active anterior rhinomanometry (aar) measures on 4 parallel groups of children with different rhinitis phenotypes, and 1 group of control (healthy) children. secondary objectives are: i) assessing of association between aar, exhaled feno (efeno) and nasal feno (nfeno); ii) assessing association between objective measurements (aar, efeno and nfeno) and subjective measurements (total 5 symptom score, t5ss). the study is intended to obtain useful information for improving rhinitis management.


Eligibility criteria:
healthy volunteers (hc) the inclusion criteria for hc are: 1. negative bronchodilator response; 2. no major nasal septum malformations. the exclusion criteria for hc are: 1. upper airway infections in the previous 4 weeks; 2. active smoker; 3. lifetime history of asthma, rhinitis, or respiratory disease symptoms. children with non allergic rhinitis (nar) the inclusion criteria for nar are: 1.t5ss\>5 in the last 4 weeks. the exclusion criteria for nar are: 1. at least one positive skin prick test for aeroallergens; 2. upper airway infections in the previous 4 weeks; 3. active smoker; 4. major nasal septum malformations. rhinitis children, perennial allergy (par) the inclusion criteria for par are: 1. t5ss\>5 in the last 4 weeks. 2. at least one positive skin prick test for perennial aeroallergens; the exclusion criteria for par are: 1. at least one positive skin prick test for seasonal aeroallergens; 2. upper airway infections in the previous 4 weeks; 3. active smoker; 4. major nasal septum malformations. rhinitis children, seasonal allergy, outside season (osr) the inclusion criteria for osr are: 1. t5ss\>5 in the last 4 weeks. 2. at least one positive skin prick test for seasonal aeroallergens; the exclusion criteria for osr are: 1. at least one positive skin prick test for perennial aeroallergens; 2. upper airway infections in the previous 4 weeks; 3. active smoker; 4. major nasal septum malformations. rhinitis children, seasonal allergy, within season (osr) the inclusion criteria for osr are: 1. t5ss\>5 in the last 4 weeks. 2. at least one positive skin prick test for seasonal aeroallergens; the exclusion criteria for osr are: 1. at least one positive skin prick test for perennial aeroallergens; 2. upper airway infections in the previous 4 weeks; 3. active smoker; 4. major nasal septum malformations.
optimized peak vo2 in predicting advanced hf

Conditions: Heart Failure; Morality; Transplant; Failure, Heart

Summary: the ability and timely selection of severe heart failure (hf) patients for cardiac transplantation and advanced hf therapy is challenging. peak vo2 by cardiopulmonary exercise test (cpet) was used for transplant listing. this study aimed to reassess the prognostic significance of peak vo2 and to compare that with the heart failure survival score in the current optimized novel guideline-directed medical therapy (gdmt).

investigators retrospectively collected acute hf patients discharged alive from the hospital. investigators divided participants into more-gdmt (≥2 kinds) and few-gdmt (\<2 kinds) groups and compared the prognostic significance of peak vo2 and hfss for combined all-cause mortality and urgent cardiac transplantation.

Eligibility criteria:
inclusion criteria: * acute hf patients with reduced ejection fraction (left ventricular ejection fraction, lvef \<=40%) and discharged alive from the hospital * patients with age \>= 20 years of age * patients who performed cardiopulmonary exercise test (cpet) within one month after discharge * patients with serum b-type natriuretic peptide (bnp) level \>100 pg/ml. exclusion criteria: * patients with estimated survival time \< 6 months * patients who could not tolerate exercise test due to muscular-skeletal disorder or other reason * patients who had severe valvular heart disease.

Keywords: advance heart failure cardiac transplantation peak oxygen consumption guideline-directed medical therapy risk score heart failure survival score
sleep apnea screening

Conditions: Sleep Apnea/Hypopnea Syndrome

Summary: to assess the incidence of sleep apnea-hypopnea syndrome (sahs), both obstructive and central, in patients with: 1) pacemaker indication; 2) implantable cardioverter defibrillator (icd) or cardiac resynchronization therapy (crtd), 3) heart failure and preserved left ventricular ejection fraction (lvef) and 4) heart failure and reduced lvef.


Eligibility criteria:
inclusion criteria: * age 18 years or older * no previous diagnosis of sleep apnea * fulfilling at least one of the following: 1. pacemaker indication 2. icd or crtd therapy indication 3. heart failure and preserved lvef (40-50%) 4. heart failure and reduced lvef (\<40%) * signed informed consent exclusion criteria: * age younger than 18 years * renal hemodialysis * cardiac transplant indication * women who are pregnant * advanced cancer * enrollment in another investigational study * able and willing to comply with all testing and requirements * patient not suitable for inclusion due to psychiatric conditions or short life expectancy
cord milking and activity of the immune system in preterm infants

Conditions: Preterm Delivery

Summary: in the embry life there is a passage of igg type, from the mother to tha embryoyo and only in the age of 3-5 month after birth the infant start to develop them by himself. in preterm infants the starting point of the level of the igg's is lower from the level of term infants. delayed cord clamping /milking it was prooved in many researches as benificial in terms of : levels of hemoglobin; hematocrit and feritin in the neonats. also benefits were proved by means of less need for blood tranfusion, less intra ventricular hemorrhage; necrotzing entero colitis and iron deficiency anemia. the hypothesis is that delayed clamping /milking it will increse the level of igg's in preterm infants. the end point hypothesis is that delayed cord clamping /milking cause to less fever disease or hospitalization it the neonats.

in this study we come to a prove that if we miking the cord in preterm infats we will increse the level of igg .

Eligibility criteria:
inclusion criteria: * preterm infans between 24+0/7 to 36 * 6/7 weeks. * newborn for mother who agree to participate in the research who deliver in normal delivery / planed or urgent cesarian delivery exclusion criteria: * intra uterine growth restriction, infant under 10% to age of pregnancy. * mother who is not willing to participate in research. * neonates to mother whom suspected to be immuno- compromised or having infection around delivery.

Keywords: delayed cord clamping milking of cord premature infants level of igg in neonates
evaluate the meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy

Conditions: Metastatic Breast Cancer

Summary: a randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.

the study population designed to be enrolled is patients with histologically and/or cytologically confirmed breast cancer with clinical evidence of recurrent or progressive metastatic disease and at least completed 3 cycle chemotherapy regimen who have evidence of fatigue.

Eligibility criteria:
inclusion criteria: 1. female patients over 20years old and under 80 years old. 2. estrogen receptor (er), progesterone receptor (pr) and human epidermal growth factor receptor (her2), these 3 indicators are all negative. 3. after at least 3 cycles of chemotherapy. 4. sign the subject informed consent form (icf). exclusion criteria: 1. have received other clinical studies within 3 weeks 2. any uncontrollable infection 3. history of lupus erythematosus, rheumatoid arthritis, ankylosing spondylosis, scleroderma or multiple sclerosis 4. history of cancer cells that have metastasized to the brain 5. currently receiving a mixture of three or more types of cytotoxic chemotherapy drugs 6. currently using anti-fatigue treatments, including psychostimulants, acupuncture, etc. note: antidepressants are used for treatment to relieve fatigue (such as depression or hot flashes) is allowed, 7. need to use long-acting sustained-release pain narcotic analgesics 8. uncontrollable nausea, vomiting or other symptoms that will hinder the ability to speak about the test product 9. any other serious illness/history that would limit the patient's ability to receive study treatment, as determined by the researcher evaluate 10. lactation, pregnancy or planning pregnancy 11. people with cardiovascular disease or severe liver and kidney dysfunction should not drink it within one week after surgery.

Keywords: metastatic breast cancer fatigue
vialize use for the reduction of vascular groin incisional dehiscence and infection

Conditions: Vascular Diseases

Summary: groin incisions in vascular surgery have complications in up to 30% of cases at 30 days, resulting in reductions in patient quality of life and increased costs. prior attempts at reducing this complication rate have been largely unsuccessful. the purpose of this study is to determine the feasibility of routine vialize use for vascular surgeries involving a groin incision and to determine the rates of surgical site infection/dehiscence in such patients receiving subcutaneous vialize.


Eligibility criteria:
inclusion criteria: * the study population will consist of patients undergoing vascular procedures with groin incisions. patients must be at least 18- years-old and able to complete baseline measurements. all subjects will be compensated. patients undergoing treatment for peripheral arterial disease (e.g., femoropopliteal bypass), aneurysm disease (e.g., aortofemoral bypass), end-stage kidney disease (e.g., loop thigh graft), and miscellaneous procedures (e.g., femoral exposure for delivery of device) will be eligible. exclusion criteria: * patients undergoing use of negative pressure wound therapy (e.g., prevena) and local antibiotic placement (e.g., vancomycin powder) will be excluded. additionally, organ-transplant recipients will be excluded.

Keywords: groin infections quality of life readmission groin incisions
clinical translation of a novel fapi dimer [68ga]ga-lnc1013

Conditions: Gastrointestinal Cancer

Summary: fibroblast activation protein (fap) emerges as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. to exploit the therapeutic potential of current fap inhibitors (fapis), this study presented the design and synthesis of a series of fapi dimers to increase tumor uptake and retention. preclinical evaluation and a pilot clinical pet imaging study were conducted to screen the lead compound with the potential for radionuclide therapy.

three new fapi dimers were synthesized by linking two quinoline-based fapis with different spacers. the in vitro binding affinity and preclinical small animal pet imaging of the compounds were compared with their monomeric counterparts, fapi-04 and fapi-46. the lead compound, 68ga-lnc1013, was then evaluated in a pilot clinical pet imaging study involving seven patients with gastrointestinal cancer.

Eligibility criteria:
inclusion criteria: 1. histologically and/or clinically confirmed and/or suspicious of gastrointestinal cancer. 2. signed informed consent. exclusion criteria: 1. pregnancy; 2. breastfeeding; 3. any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Keywords: fapi dimer